Kayexalate Calcium (Calcium Polystyrene Sulfonate)

Kayexalate Calcium is employed in the management of conditions characterized by elevated potassium levels.

• Hyperkalemia: lowers serum potassium concentrations in patients with acute or chronic elevation.
• Acute hyperkalemia: provides rapid potassium removal when urgent reduction is clinically required.
• Chronic hyperkalemia: assists in maintaining potassium balance in patients with persistent excess.
• Renal failure-associated hyperkalemia: helps control potassium levels when renal excretion is impaired.
• Cardiac risk due to hyperkalemia: reduces the likelihood of arrhythmias by decreasing serum potassium.

• Calcium Polystyrene Sulfonate is a cation exchange resin that remains in the gastrointestinal lumen. Its polymer matrix contains calcium ions that exchange with potassium ions present in the intestinal contents. The bound potassium is not absorbed and is eliminated in the feces, thereby decreasing the amount of potassium reabsorbed into the bloodstream and lowering serum potassium levels.

Kayexalate Calcium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Constipation: reduced bowel movements leading to hard stools.
• Nausea: feeling of sickness or urge to vomit.
• Vomiting: expulsion of stomach contents.
• Abdominal discomfort: cramping or pain in the stomach area.
• Diarrhea: loose, watery stools.
• Taste alteration: metallic or unpleasant taste.
• Flatulence: increased gas production.

Serious or Rare Side Effects

• Intestinal necrosis or perforation: severe damage to the bowel wall that may require surgery.
• Severe electrolyte disturbances: significant drops in calcium or rises in calcium levels.
• Allergic reactions: rash, itching, swelling, or anaphylactic response.

Before prescribing Kayexalate Calcium, clinicians should consider several safety precautions to minimize risks.

• Assess baseline serum potassium: confirm hyperkalemia, determine severity, and document values.
• Monitor calcium levels: regularly check serum calcium to detect hypocalcemia or hypercalcemia.
• Use cautiously in patients with bowel disorders: constipation, ulcerative colitis, or recent surgery increase risk of intestinal injury.
• Avoid in severe hypocalcemia: the resin may further lower calcium and exacerbate symptoms.
• Adjust use in renal impairment: reduced kidney function may alter potassium handling; monitor closely.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Kayexalate Calcium can affect the absorption or action of several concomitant medicines.

Major Interactions (Avoid)

• Oral potassium supplements: simultaneous use may reduce the effectiveness of potassium supplementation.
• Antacids containing aluminum or magnesium: can bind the resin and diminish potassium removal.
• Calcium‑containing medications: may compete for exchange sites, lowering resin efficacy.
• Iron supplements: binding may reduce iron absorption, avoid co‑administration.

Moderate Interactions (Monitor Closely)

• Levothyroxine: resin may decrease its absorption; separate administration by at least 4 hours.
• Digoxin: monitor serum digoxin levels as binding may alter its bioavailability.
• ACE inhibitors or ARBs: combined effect on potassium; monitor serum potassium closely.
• Loop diuretics: may increase potassium loss; monitor potassium levels.